Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Left ventricular hypertrophy--an important, often unrecognized risk factor]

L Lind1, B Andren

  • 1Medicinkliniken, Akademiska Sjukhuset, Uppsala.

Lakartidningen
|September 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolome-wide association study identifies metabolites associated with human exposure to perfluoroalkyl substances.

Journal of exposure science & environmental epidemiology·2026
Same author

An interpretable molecular descriptor for machine learning predictions in atmospheric science.

The Journal of chemical physics·2026
Same author

Longitudinal and cross-sectional analysis of perfluoroalkyl substances and kidney function.

Journal of exposure science & environmental epidemiology·2025
Same author

Risk of venous thromboembolism in relation to high physical activity level in men over 27 year follow up.

Journal of thrombosis and thrombolysis·2024
Same author

Plasma perfluoroalkyls are associated with decreased levels of proteomic inflammatory markers in a cross-sectional study of an elderly population.

Environment international·2020
Same author

Using proximity extension proteomics assay to discover novel biomarkers associated with circulating leptin levels in patients with type 2 diabetes.

Scientific reports·2020
Same journal

[Access to health data for research].

Lakartidningen·2026
Same journal

[CANVAS and RFC1-related disease - a broad clinical spectrum from cough and neuropathy to cerebellar ataxia].

Lakartidningen·2026
Same journal

[Choosing wisely in Swedish neuroradiology].

Lakartidningen·2026
Same journal

[Asthma among athletes - prevalence, diagnosis and treatment].

Lakartidningen·2026
Same journal

[Minimally invasive surgery for colorectal cancer was introduced in a safe and well controlled manner].

Lakartidningen·2026
Same journal

[Modified Valsalva maneuver induced an asymptomatic polymorphic ventricular tachycardia].

Lakartidningen·2026
See all related articles

Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events in hypertensive patients. Studies suggest that reducing LVH may decrease cardiovascular risk, pending clinical trial confirmation.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Echocardiography

Context:

  • Left ventricular hypertrophy (LVH) identified via echocardiography is a potent cardiovascular risk factor in both general and hypertensive populations.
  • While commonly linked to hypertension, LVH develops in less than half of hypertensive individuals.
  • Factors implicated in LVH development include insulin resistance, endothelial dysfunction, increased blood viscosity, reduced arterial compliance, and elevated angiotensin-converting enzyme activity.

Purpose:

  • To review the established link between left ventricular hypertrophy (LVH) and cardiovascular events.
  • To explore the multifactorial etiology of LVH in hypertensive patients.
  • To discuss the potential benefits of LVH regression on cardiovascular risk.

Summary:

Related Experiment Videos

  • Epidemiological data confirm left ventricular hypertrophy (LVH) as a major predictor of cardiovascular events.
  • The development of LVH in hypertension is multifactorial, involving metabolic and hemodynamic factors.
  • Observational studies indicate that regression of LVH may reduce cardiovascular risk, though prospective trials are ongoing.

    • Impact:

    • Highlights LVH as a critical target for cardiovascular risk reduction strategies in hypertension.
    • Underscores the need for further clinical trials to validate the benefits of LVH regression.
    • Informs clinical practice regarding the assessment and management of hypertensive patients at risk for cardiovascular events.